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Introduction
Brachiocephalic veins (BCVs) and the superior vena cava 
(SVC) are critical areas vulnerable to tumours arising from 
the anterior mediastinal compartment, such as thymomas, 
thymic carcinoma, thyroid neoplasm, and germ cell 
tumours, as well as right-sided pulmonary neoplasms. The 
type of resection and reconstruction of BCVs or the SVC 
depends on the extent of vessel defect: partial resection 
and direct repair (with or without a patch) or complete 
resection and prosthetic replacement (1). Prosthetic graft 
interposition in patients undergoing SVC resection due to 
extensive infiltration can be safely performed; moreover, 
it can ensure sufficient tumour-free resection margins and 
adequate blood flow (2). 
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However, resection and reconstruction of the SVC 
is still considered surgically challenging and is rarely 
performed, which is why no standard technique has yet 
been implemented (3). Moreover, prognosis depends on 
which surgical strategy or technique is employed, on which 
replacement material is chosen, and on the number of 
complications encountered, such as graft occlusion and/or 
infection. 
Graft occlusion caused by graft thrombosis or local 
tumour recurrence may have a detrimental effect on surgical 
complications. However, few data are available on graft 
occlusion after prosthetic graft interposition. Furthermore, 
the correlation between graft patency and the various types 
of prosthetic graft interpositions remains unknown. Thus, we 
assessed graft patency and its correlation with the various types 
of graft interposition. We evaluated the risk factors for graft 
occlusion to establish optimal surgical strategies in patients 
undergoing prosthetic graft interposition of the BCVs or the 
SVC, combined with resection of malignant tumours.
Materials and methods
Patients
All patients undergoing surgery were prospectively 
registered in the database at ASAN Medical Center, which 
records baseline patient characteristics, results of the 
preoperative evaluation, detailed information on surgery, 
perioperative treatment, and follow-up status. This registry 
was screened to identify patients who underwent prosthetic 
reconstruction of the BCVs or the SVC combined with 
resection of malignant tumours between November 1998 
and February 2012. All patients who had undergone partial 
resection with or without patch angioplasty were excluded 
from this study. A total of 16 patients were enrolled in this 
study. The following data were collected to identify the 
correlation between graft patency: graft material, diameter, 
the presence of an external ring, proximal anastomosis site, 
distal anastomosis site, and anticoagulation therapy.
Surgery
Median sternotomy was the most common approach to 
anterior mediastinal tumours. Concomitant pulmonary 
resections included lobectomy in one patient and 
wedge resection in nine patients. One patient with lung 
adenocarcinoma in the right upper lobe underwent 
lobectomy through a right posterolateral thoracotomy, 
followed by SVC resection and reconstruction through a 
median sternotomy. 
After the BCVs and/or the SVC were resected, graft 
interposition was performed in a variety of ways. Figure 1 
shows the various types of prosthetic graft interpositions. 
These included graft interposition from the distal SVC to the 
proximal SVC (Figure 1A, n=3), from the right BCV to the 
SVC or right atrial appendage (RAA) (Figure 1B, n=5), bilateral 
BCVs reconstruction with separate grafts (Figure 1C, n=4), 
from the left BCV to the RAA or SVC (Figure 1D, n=3), and 
graft interposition of the segmental left BCV (Figure 1E, n=1).
For cavo-caval anastomosis (SVC interposition), the 
extrapericardial portion of the SVC was prepared and 
the intrapericardial SVC portion was exposed. When 
A B C D E
Figure 1 Types of prosthetic graft interposition in the present series. (A) Reconstruction of segmental SVC (n=3); (B) sole right BCV 
reconstruction (n=5); (C) bilateral BCV reconstruction with two separate grafts (n=4); (D) sole left BCV reconstruction (n=1); (E) 
reconstruction of segmental left BCV (n=1). SVC, superior vena cava; BCV, brachiocephalic vein.
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infiltration involved one or both BCVs, the prosthesis was 
placed between the BCV and the SVC (BCV-SVC, with 
cross clamping) or between the BCV and the RAA (BCV-
RAA, without SVC cross clamping). Cardiopulmonary 
bypass was not performed on any patients.
The diameter of the grafts ranged from 8 to 20 mm. 
The median diameter of the right BCV or the SVC 
grafts was 14 mm (range, 10–18 mm) and that of the left 
BCV grafts was 10 mm (range, 8–20 mm). All patients 
received intravenous heparin sodium (50–100 U/Kg) 
5–10 min before vascular occlusion. After intraoperative 
heparinization, the partial thromboplastin time (PTT) 
was allowed to normalise without pharmacologic reversal. 
Thirteen patients were discharged with warfarin therapy, 
and most patients received anticoagulation therapy 
for a minimum of 6 months. Patients were selectively 
transitioned to an antiplatelet agent or warfarin at the 
surgeon’s discretion.
Follow-up
The median follow-up duration was 42 months (range, 
1–107 months). Graft patency was verified by means of 
venography or contrast enhanced computed tomography. 
Statistical analysis
Kaplan-Meier curves were used to delineate graft patency, 
and log-rank tests were used to compare the between-
group differences in the rates. For univariable analyses, the 
Cox-proportional hazards model was used to determine the 
risk factors of graft occlusion. All statistical analyses were 
performed using IBM SPSS 18.0 (New York, NY, USA) and 
a P value <0.05 was considered statistically significant.
Results
Baseline characteristics of patients and grafts
Clinicopathologic features of patients and prosthetic graft 
interposition were shown in Table 1. The median age was 
50 years old (range, 17–75 years old). Fourteen patients 
were male. The indications for surgery were thymic 
carcinoma in 43.8% of patients (7/16), thymoma in 31.3% 
of patients (5/16), mediastinal germ cell tumours in 12.5% 
of patients (2/16), non-small cell lung cancer in 6.3% of 
patients (1/16), and lymphoma in 6.3% of patients (1/16). 
Preoperative chemotherapy or chemoradiation therapy 
were administered to 56.3% of patients (9/16). 
Operative mortality and overall survival
Operative mortality was not observed. The 5-year overall 
survival rate was 66.7%. The 3-year overall survival rate 
after surgery was 100% for lung cancer and lymphoma, 
83.3% for thymic epithelial tumours (thymic carcinoma, 
thymoma), and 0% for germ cell tumours.
Graft patency and follow-up
Out of a total of 20 grafts in 16 patients, eight grafts in 
eight patients were occluded. The median duration to graft 
occlusion was 5 months (range, 1–41 months). Among the 
eight patients with graft occlusion, four patients experienced 
occlusive symptoms such as headache, facial swelling, and 
upper extremity edema. For three out of four patients with 
occlusive symptoms, these symptoms improved over a period 
of 1, 3, and 6 months following treatment using diuretics and 
low molecular weight heparin (Figure 2). One patient who 
received SVC graft interposition using a Hemashield graft 
had severe symptoms due to extraluminal compression from 
a recurring mediastinal lymph node originating from lung 
cancer; therefore, he received SVC stent insertion. After the 
insertion, his symptoms improved immediately.
Five-year patency for all 20 grafts was 42.4% (Figure 3A). 
Two-year patency for the right BCV or the SVC grafts was 
81.8%, whereas for the left BCV grafts it was 38.1%, Patency 
of the left BCV graft was significantly lower than that of the 
right BCV or the SVC graft (P=0.024, Figure 3B).
Risk factors for graft occlusion
According to univariate analysis using the Cox-proportional 
hazards model, the superior anastomosis site (left BCV 
vs. right BCV or SVC; HR =2.312; 95% CI, 1.015–5.265; 
P=0.046), the inferior anastomosis site (right atrial 
appendage vs. remnant SVC; HR =2.409; 95% CI, 1.124– 
5.161; P=0.024), and interruption of warfarin (HR =5.015; 
95% CI, 1.106–22.734; P=0.037) were all significant risk 
factors for graft occlusion, whereas graft diameter (P=0.076) 
or the presence of an external stent (P=0.470) were not 
significant factors.
Discussion
SVC reconstruction is not considered to be a contraindication 
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for the resection of a bronchopulmonary or mediastinal 
neoplasm in an otherwise potentially curable patient (4,5). 
Appropriate indications and surgical techniques for graft 
interposition of the SVC or the BCVs are documented to 
have clear benefits in a select group of patients. Complete 
prosthetic replacement has not been shown to increase 
overall postoperative morbidity in patients undergoing SVC 
resection and it can be performed when other reconstruction 
techniques preclude sufficient tumour-free resection margins 
or compromise adequate blood flow (2,5).
Ringed polytetrafluoroethylene (PTFE) grafts have 
been used for the reconstruction of mediastinal veins 
with considerable success (6). Various strategies for graft 
interposition of BCVs or the SVC have been previously 
investigated (2,4,6-9); however, an optimal strategy remains 
unclear because the procedure is uncommon, and data 
regarding long-term graft patency are limited. Thus, this 
study focused on the correlation between long-term patency 
and surgical strategies and techniques of each graft rather 
than on the oncologic survival outcomes of the patients. 
Eight (50%) out of 16 patients in this study experienced 
graft occlusion. The incidence was relatively high compared 
to previous studies, which report an overall thrombosis 
rate of PTFE reconstruction of the SVC between 14–24% 
within 3 to 5 years (3,10). A possible explanation for these 
results may be that the SVC reconstructions in our study 
Figure 2 Representative computed tomographic images with contrast enhancement in a patient suffering from acute occlusive symptoms for 
6 months due to graft occlusion, which occurred 4 months after initial surgery. (A) The image shows an occlusion of the left BCV graft and 
swelling of the anterior chest wall at the time of symptoms; (B) an image obtained 6 months later, showing newly developed collateral vessels 
and a mild improvement in the swelling of the chest wall, but also showing a large amount of right pleural effusion still remaining; (C) an 
image obtained 12 months later, showing more collateral vessels and a definite improvement in chest wall swelling.
A B C
Figure 3 Graft patency of 20 grafts in 16 patients. (A) Overall graft patency; (B) graft patency stratified by interposed vessels.
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were performed by different cardiac surgeons who used 
different graft interposition techniques based on their 
individual preferences. Going forward, it may be necessary 
to establish an standardized optimal policy for SVC 
reconstruction performed by one experienced surgeon only, 
in order to ensure hospital-wide quality control.
In this study, four out of eight patients (50%) who 
experienced graft occlusion presented clinical symptoms. 
All symptomatic patients had undergone unilateral graft 
interposition. Based on these findings, we speculate that 
unilateral graft interposition should be avoided to prevent 
significant occlusive symptoms. We observed that the 
duration of occlusive symptoms ranged from 1 to 6 months. 
Patients experiencing graft occlusion can present with 
various combinations of the following symptoms: neck-
face swelling, jugular distention, facial erythrosis, dyspnea, 
headache, and dry cough (5). The severity of the SVC 
syndrome depends mainly on the rate of progression of 
SVC obstruction and the degree of development of venous 
drainage (11,12). For patients with symptomatic graft 
thrombosis, oral anticoagulation therapy is the first line of 
therapy to promote the development of collateral venous 
circulation and reduce clinical manifestations. Medical 
treatment, including anticoagulation therapy, elevating the 
head at night, corticosteroids, or diuretics during the acute 
phase can also be useful (8).
In a study by Lanuti et al., unilateral reconstruction of 
the BCVs yielded satisfactory long-term patency (4). In 
this study, graft patency of the left BCV was inferior to 
that of the right BCV or the SVC. We speculate that the 
difference in graft patency between the right and left BCVs 
may have resulted from problems in the left BCV prosthetic 
graft interposition. Firstly, the prosthetic graft can kink the 
left BCV at the superior anastomosis site. Secondly, the 
left BCV can be compressed between the sternum and the 
ascending aorta. Thirdly, flow velocity tends to be slower 
in the left graft because it is longer in length. Fourthly, 
pectinate muscles in the RAA might create turbulence in the 
blood flow, causing functional failure of the venous system 
and inadequate venous return against resistance represented 
by the pectinate muscle of the right atrium at the inferior 
anastomosis site (2). To prevent anastomosis site kinking, 
it is recommended that to cut and trim the proximal and 
distal ends as sigmoid curves in order to ensure a wider 
orifice, allowing smooth blood flow and preventing kinking 
of the graft after closing the chest. In addition, the route of 
the graft should be avoid crossing the ascending aorta and 
sternum, and the pectinate muscle in the RAA should be 
completely resected around inferior anastomosis site. 
Univariate analyses revealed that potential risk factors 
related to graft occlusion were left BCV anastomosis (vs. 
right BCV) and RAA anastomosis (vs. SVC). Of these risk 
factors, sole reconstruction of the left BCV between the 
RAA should be avoided in patients undergoing resection of 
the SVC and the left BCV. Although it is technically more 
difficult to perform a right BCV to graft anastomosis than 
a left BCV to graft anastomosis, this approach results in 
minimal graft angulation and direct downward blood flow 
aided by gravity (8). In addition, an advantage of using 
bilateral grafts is that even if one of the grafts is occluded 
by thrombus formation or local tumour recurrence, the 
other will likely remain patent (13). Moreover, bilateral 
reconstruction of BCVs is recommended to prevent 
significant subclavian venous hypertension and secondary 
lymphatic occlusion, as well as respiratory insufficiency.
There has been controversy regarding the role of 
anticoagulation therapy after graft interposition of 
BCVs or the SVC (3,6,10), and an optimal duration of 
anticoagulation therapy has not been established. Shintani 
et al. suggested that longer anticoagulation therapy beyond 
6 months might be necessary for patients who have 
undergone reconstruction of both BCVs to prevent late 
graft occlusion (6). This practice was based on concerns 
that a prosthetic graft in a low-pressure flow vascular 
system such as BCVs or the SVC would be more prone to 
thrombosis. On the other hand, Okereke et al. reported 
38 patients who underwent SVC reconstruction with 
externally stented-PTFE vascular prostheses (8). They 
opted for daily aspirin only, and did not observe an excessive 
thrombosis rate. In our study, warfarin was prescribed 
to 13 out of 16 patients at discharge, for a period of 3 to 
6 months. After that, most patients who interrupted 
warfarin were treated with aspirin with or without 
clopidogrel bisulfate. However, we observed graft 
thrombosis after interruption of warfarin even if aspirin 
with or without clopidogrel bisulfate was administrated 
orally. Therefore, we believe that long-term anticoagulation 
therapy is necessary to prevent graft thrombosis.
This study has important limitations, mostly stemming 
from its small sample size and retrospective design. A 
chief issue raised and unsolved in this study is the optimal 
duration of warfarin therapy. A future large-scale study 
is necessary to ascertain optimal surgical strategies and 
management techniques that can guarantee long-term graft 
patency.
In conclusion, prosthetic graft interposition between 
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the left BCV and the right atrial appendage resulted 
in a significant rate of graft occlusion. Prosthetic graft 
interposition of the bilateral BCVs and long-term warfarin 
therapy may be necessary to prevent graft occlusive 
symptoms.
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